Ronald Cooper
Chief Executive Officer at ALBIREO PHARMA, INC.
Net worth: 28 595 $ as of 29/04/2024
Ronald Cooper active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ALBIREO PHARMA, INC. | Chief Executive Officer | 31/05/2015 | - |
| Director/Board Member | 31/10/2016 | 01/03/2023 | |
| President | 31/05/2015 | 01/03/2023 | |
| GENERATION BIO CO. | Director/Board Member | 28/02/2021 | - |
| Independent Dir/Board Member | - | - | |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Director/Board Member | 31/08/2015 | - |
| Chief Executive Officer | 30/06/2015 | 31/10/2016 | |
| President | 30/06/2015 | 31/10/2016 | |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Director/Board Member | - | - |
| Chief Executive Officer | - | - | |
| President | - | - |
Career history of Ronald Cooper
Former positions of Ronald Cooper
| Companies | Position | Start | End |
|---|---|---|---|
| GENOCEA BIOSCIENCES, INC. | Director/Board Member | 06/06/2016 | 11/04/2021 |
| Independent Dir/Board Member | 06/06/2016 | 11/04/2021 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 31/12/2007 | 31/10/2015 |
Training of Ronald Cooper
| St. Francis Xavier University | Undergraduate Degree |
Statistics
International
| United States | 5 |
| Canada | 2 |
| United Kingdom | 2 |
Operational
| Director/Board Member | 5 |
| Chief Executive Officer | 3 |
| President | 3 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENERATION BIO CO. | Health Technology |
| Private companies | 3 |
|---|---|
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Ronald Cooper
- Experience
